T-cell treatment for lung cancer that has spread
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has spread (stage IV) or cannot be removed, and you’re not eligible for neuroendocrine tumors
- You have at least one tumor spot that can be surgically removed so the study can grow tumor-fighting T cells (TILs)
- Your cancer has already been treated with at least one initial (first-line) systemic therapy, and it has gotten worse
- Brain metastases are allowed only if there are 3 or fewer, they’re under 1 cm, and they’re not causing symptoms; treated spots must be stable
- You must have a generally good body status (ECOG 0 or 1) and be age 18 to 72
- You need to meet immune and blood/organ lab thresholds and be free of HIV and active hepatitis infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer. The cells are taken from a tumor, multiplied in a lab, and given back to you to help your body attack the cancer.
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial tests a personalized treatment using your own immune cells (T cells) that are specially trained to find and attack lung cancer cells. It may help people with advanced or relapsed lung cancer who have not improved with standard treatments.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.